For the first time, we discovered that SFI could attenuate myocardial hypertrophy, probably through up-regulating or maintaining the miR-19a-3p level, decreasing MEF2A mRNA and protein expressions, and regulating the protein expression of β-MHC, BNP and TRPC1 of the MEF2 signaling pathway. Here, TRPC1 is linked to cardiac hypertrophy.